Belite Bio, Inc (BLTE)
| Market Cap | 6.62B +71.2% |
| Revenue (ttm) | n/a |
| Net Income | -110.95M |
| EPS | -2.83 |
| Shares Out | 40.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 216,974 |
| Open | 170.75 |
| Previous Close | 169.96 |
| Day's Range | 156.43 - 170.75 |
| 52-Week Range | 105.88 - 200.00 |
| Beta | -1.19 |
| Analysts | Strong Buy |
| Price Target | 231.78 (+41.02%) |
| Earnings Date | Nov 12, 2026 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $231.78, which is an increase of 41.02% from the latest price.
News
Belite Bio price target raised to $215 from $185 at Leerink
Leerink raised the firm’s price target on Belite Bio (BLTE) to $215 from $185 and keeps an Outperform rating on the shares. The firm notes Belite’s Q3 update was largely…
Belite Bio Earnings Call Transcript: Q3 2026
Tinlarebant’s U.S. NDA has priority review and a Feb. 12, 2027 PDUFA date, with international filings and launch preparations advancing. Q3 GAAP net loss was $30.3 million, and quarter-end cash and Treasury bills totaled $774 million.
Belite Bio Earnings release: Q3 2026
Belite Bio released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Belite Bio reports Q3 non-GAAP EPS (26c), consensus (77c)
As of September 30, 2026, the company had $271.3M in cash and cash equivalents vs. $352.9M on December 31, 2025. “As we advance toward our PDUFA target action date of…
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio price target lowered to $221 from $234 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Belite Bio (BLTE) to $221 from $234 and keeps an Outperform rating on the shares.
Belite Bio announces uplisting to Nasdaq Global Select Market
Belite Bio (BLTE) announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading…
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio submits MAAs for tinlarebant in Singapore, UK and Switzerland
Belite Bio (BLTE) announced marketing authorization application, or MAA, submissions to the regulatory authorities in Singapore, the United Kingdom, and Switzerland for tinlarebant in the treatment of...
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio management to meet with Piper Sandler
Meeting to be held in New Orleans on October 9 hosted by Piper Sandler.
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Tinlarebant's efficacy in Stargardt disease is supported by robust clinical and natural history data, with consistent benefits across patient subgroups and manageable side effects. Broad applicability and strong payer support are expected, with sufficient capital for commercialization.
Belite Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Tinlarebant slowed DDAF lesion progression by 36% over two years in DRAGON, and its Stargardt NDA has FDA priority review with a Feb. 12 PDUFA date. Launch planning targets retinal specialists, while PHOENIX and Japan-focused DRAGON II continue.
Belite Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
FDA and Japan reviews for Tinlarebant in Stargardt disease are progressing, with strong efficacy and safety data supporting broad use. Competitive analysis highlights Tinlarebant's advantages, and commercialization plans focus on genetic testing, awareness, and patient support.
Belite Bio price target raised to $234 from $220 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $234 from $220 and keeps an Outperform rating on the shares. The firm cites the company’s…
Belite Bio price target raised to $245 from $214 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $245 from $214 and keeps a Buy rating on the shares. The company announced the submission of a…
Belite Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Tinlarebant, an oral therapy for Stargardt disease and geographic atrophy, is under FDA priority review with a decision expected by February. The company anticipates broad patient eligibility, strong payer support, and manageable safety profile, while also advancing a global Phase III study in geographic atrophy.
Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1
Belite Bio (BLTE) announced the submission of a New Drug Application to the Ministry of Health, Labour, and Welfare in Japan for tinlarebant in Stargardt disease type 1. Tinlarebant is…
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targe...
Canaccord starts Belite Bio at Buy on additional post-IPO upside
Canaccord analyst Whitney Ijem initiated coverage of Belite Bio (BLTE) with a Buy rating and $303 price target The firm sees drivers for additional share upside over the near and…
Belite Bio initiated with a Buy at Canaccord
Canaccord initiated coverage of Belite Bio (BLTE) with a Buy rating and $303 price target
Belite Bio Transcript: Investor update
FDA has accepted the NDA for tinlarebant in Stargardt disease type 1, with priority review and a PDUFA date set for February 2027. Clinical data show significant efficacy and safety, and commercial preparations are advanced, targeting a large unmet need with robust physician and patient interest.
Belite Bio Slides: Investor update
Belite Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.